{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:39Z","timestamp":1792839699695,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jceh.2022.04.020","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:11:55Z","timestamp":1651756315000},"page":"1276-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt"],"prefix":"10.1016","volume":"12","author":[{"given":"Mohamed S.","family":"Abdelbary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7469-6483","authenticated-orcid":false,"given":"Reham","family":"Samir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed M.","family":"El-Nahaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha M.H.","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omnia","family":"Tantawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa A.","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Yosry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2022.04.020_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11908-009-0017-3","article-title":"Reactivation of hepatitis B: pathogenesis and clinical implications","volume":"11","author":"Post","year":"2009","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jceh.2022.04.020_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/hepr.12578","article-title":"Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus\/hepatitis C virus co-infection","volume":"46","author":"Takayama","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jceh.2022.04.020_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcv.2016.02.026","article-title":"Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge","volume":"78","author":"De Monte","year":"2016","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jceh.2022.04.020_bib4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/liv.13874","article-title":"Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: a cohort study from Egypt and meta-analysis of published data","volume":"38","author":"El Kassas","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2022.04.020_bib5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/MCG.0000000000000986","article-title":"Risk of hepatitis B virus reactivation among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection","volume":"52","author":"Yanny","year":"2018","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jceh.2022.04.020_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2017.05.021","article-title":"Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice","volume":"93","author":"Loggi","year":"2017","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jceh.2022.04.020_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cgh.2016.06.023","article-title":"Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents","volume":"15","author":"Wang","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.04.020_bib8","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jgh.13771","article-title":"Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals","volume":"32","author":"Yeh","year":"2017","journal-title":"J.\u00a0Gastrenterol. Hepatol."},{"key":"10.1016\/j.jceh.2022.04.020_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/trstmh\/trz079","article-title":"Sofosbuvir-\/Daclatasvir-based therapy for chronic HCV and HCV\/hepatitis B virus coinfected patients in Egypt","volume":"114","author":"Nagaty","year":"2020","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jceh.2022.04.020_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of hepatitis B virus: a review of clinical guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clinical liver disease"},{"key":"10.1016\/j.jceh.2022.04.020_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"Electronic address: easloffice@easloffice.eu; European association for the study of the liver. EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.04.020_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.04.020_bib13","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.04.020_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jviromet.2010.07.025","article-title":"Detection and quantitation of HBV DNA in miniaturized samples: multi centre study to evaluate the performance of the COBAS (R) AmpliPrep\/COBAS (R) TaqMan (R) hepatitis B virus (HBV) test v2.0 by the use of plasma or serum specimens","volume":"169","author":"Berger","year":"2010","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.jceh.2022.04.020_bib15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A\u00a0simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.04.020_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.04.020_bib17","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.04.020_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.29109","article-title":"Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.04.020_bib19","first-page":"167","article-title":"Immunosuppression and HBV reactivation","volume":"2","author":"Shouval","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jceh.2022.04.020_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.04.020_bib21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13075-018-1748-z","article-title":"Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study","volume":"20","author":"Tien","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jceh.2022.04.020_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/apt.14177","article-title":"No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort","volume":"46","author":"M\u00fccke","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2022.04.020_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/apt.13985","article-title":"Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen","volume":"45","author":"Londo\u00f1o","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2022.04.020_bib24","doi-asserted-by":"crossref","first-page":"ofx028","DOI":"10.1093\/ofid\/ofx028","article-title":"Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection","volume":"4","author":"Liu","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jceh.2022.04.020_bib25","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.cgh.2017.05.032","article-title":"Interferon-Free regimens in hepatitis B surface antigen\/anti-hepatitis C virus positive patients: the need to Control hepatitis B virus replication to avoid hepatitis B virus reactivation","volume":"15","author":"Macera","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2022.04.020_bib26","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.2147\/IDR.S215974","article-title":"Management of patients with hepatitis B virus reactivation post-DAA treatment of chronic hepatitis C virus infection in HCV-HBV coinfected patients with pretreatment HBeAg seroconversion and early degree of hepatic fibrosis","volume":"12","author":"Osman","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jceh.2022.04.020_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2020.01.027","article-title":"Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection","volume":"73","author":"Yeh","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2022.04.020_bib28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2022.04.020_bib29","doi-asserted-by":"crossref","first-page":"ofy340","DOI":"10.1093\/ofid\/ofy340","article-title":"Absence of HBV reactivation in patients with resolved HBV infection following DAA therapy for hepatitis C: a 1-year follow-up study","volume":"6","author":"M\u00fccke","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jceh.2022.04.020_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.29135","article-title":"Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals","volume":"66","author":"Belperio","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2022.04.020_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","article-title":"APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2022.04.020_bib32","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/infdis\/jiy648","article-title":"Pretreatment hepatitis B viral load predicts long-term hepatitis B response after anti-hepatitis C therapy in hepatitis B\/C dual-infected patients","volume":"219","author":"Yeh","year":"2019","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jceh.2022.04.020_bib33","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/jvh.12737","article-title":"Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C","volume":"24","author":"Kawagishi","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2022.04.020_bib34","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/liv.13469","article-title":"Hepatitis B in Egypt: a cross-sectional analysis of prevalence and risk factors for active infection from a nationwide survey","volume":"37","author":"Ismail","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2022.04.020_bib35","first-page":"1691","article-title":"An update on the treatment options for HBV\/HCV coinfection","volume":"18","author":"Sagnelli","year":"2017","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jceh.2022.04.020_bib36","first-page":"365","article-title":"Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues","volume":"31","author":"Papadopoulos","year":"2018","journal-title":"Ann Gastroenterol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688322001244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688322001244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:09:23Z","timestamp":1760854163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688322001244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0973688322001244"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2022.04.020","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2022.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}